Skip to main content
BB Biotech AG logo

BB Biotech AG — Investor Relations & Filings

Ticker · BION ISIN · CH0027659793 LEI · 391200MBZQNPFHIVKO34 SW Financial and insurance activities
Open in API
Filings indexed 267 across all filing types
Latest filing 2024-10-25 Interim / Quarterly Rep…
Country CH Switzerland
Listing SW BION

About BB Biotech AG

https://www.bbbiotech.ch/en/bb-biotech

BB Biotech AG is an investment company specializing in the fast-growing biotechnology market. With over 30 years of experience, it is one of the world's largest investors in this sector. The company's investment strategy focuses on a portfolio of publicly listed companies that are developing and commercializing novel drugs. These target companies are selected for their potential to create significant value for the healthcare system by addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
Q3 statement / Q3 financial report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report as at 30.09.2024' and contains comprehensive financial data, including consolidated interim financial statements, performance comparisons, and a shareholder letter. It covers a period shorter than a full fiscal year (nine months ending September 30, 2024), which aligns perfectly with the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-10-25 English
BB BIOTECH AG: Dr. Thomas von Planta, buy
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains detailed information regarding a transaction by a member of the administrative body ('Dr. Thomas von Planta'). Section 4 details the nature of the transaction as an 'Acquisition' of shares, including price, volume, and date. This directly corresponds to the definition of Director's Dealing (insider trades) provided in the filing definitions.
2024-09-18 English
BB BIOTECH AG: Dr. Thomas von Planta, buy
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains detailed information regarding a transaction (Acquisition) by a 'person discharging managerial responsibilities' (Dr. Thomas von Planta, Member of the administrative or supervisory body). This directly matches the definition for Director's Dealing reports, which corresponds to the filing code DIRS.
2024-07-31 English
BB Biotech AG publishes its interim report and announces a new head of its investment management team
Report Publication Announcement Classification · 100% confidence The document is a short announcement (4107 characters) that informs the public about the publication of an interim report and a leadership change. It explicitly provides links to where the actual interim report can be accessed, rather than containing the full report itself. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA). H1 2024
2024-07-26 English
EQS-News: Substantial pipeline progress at several portfolio companies offsets rate-related market volatility
Earnings Release Classification · 100% confidence The document is explicitly titled as a 'Media release as at July 26, 2024' and contains financial performance data for the 'Portfolio of BB Biotech AG as at June 30, 2024'. It details net profit/loss for Q2 2024 and H1 2024, portfolio performance, and includes a section on 'Outlook for the second half of the year'. This structure—providing key financial highlights for a specific reporting period (H1 2024/Q2 2024) immediately following the period end—is characteristic of an Earnings Release (ER). Although it contains comprehensive details, the format is that of a press release announcing results, rather than the full, detailed statutory report (which would be closer to a 10-K or a comprehensive IR). Furthermore, the document explicitly mentions the 'Interim report as at June 30, 2024' is available elsewhere, suggesting this text is the announcement of those results. Since it provides the core financial results and commentary, 'ER' (Earnings Release) is the most appropriate classification over 'RPA' (Report Publication Announcement), which is usually reserved for very short notices pointing to the report. The mention of a leadership change is secondary to the primary financial reporting nature of the document. H1 2024
2024-07-26 English
EQS-News: Substanzielle Fortschritte einiger Portfoliounternehmen federn zinsbedingte Marktvolatilität ab
Earnings Release Classification · 100% confidence The document is titled 'EQS-News: BB BIOTECH AG / Schlagwort(e): Zwischenbericht' and contains detailed financial performance metrics for the first half (1. Halbjahr) and the second quarter (2. Quartal) ending June 30, 2024. It discusses net profit/loss, portfolio performance, management changes, and provides an outlook. The key indicator is the explicit mention of performance for a period shorter than a year ('Zwischenbericht' translates to Interim Report, and the content covers H1/Q2 results). This aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not a full Annual Report (10-K), an Earnings Release (ER, which is usually just highlights), or a mere announcement of a report (RPA). H1 2024
2024-07-26 German

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.